Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review

References

• Sankaranarayanan R, Ferlay J. Worldwide burden of gynecological cancer. Handb dis burdens qual life Meas. New york: Springer; 2010. p. 803–823.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Hull R, Mbele M, Makhafola T, et al. Cervical cancer in low and middle‑income countries (review). Oncol Lett. 2020;20(3):2058. doi: 10.3892/ol.2020.11754
   PubMed Web of Science ®Google Scholar
• Guimarães YM, Godoy LR, Longatto-Filho A, et al. Management of early-stage cervical cancer: a literature review. Cancers (Basel). 2022;14(3):575. doi: 10.3390/cancers14030575
   PubMed Web of Science ®Google Scholar
• Landoni F, Maneo A, Cormio G, et al. Class II versus class III radical hysterectomy in stage IB–IIA cervical cancer: a prospective randomized study. Gynecol Oncol. 2001;80(1):3–12. doi: 10.1006/gyno.2000.6010
   PubMed Web of Science ®Google Scholar
• Shrivastava S, Mahantshetty U, Engineer R, et al. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol. 2018;4(4):506–513. doi: 10.1001/jamaoncol.2017.5179
   PubMed Web of Science ®Google Scholar
• Fachini AMD, Zuliani AC, Sarian LO, et al. Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: a randomized controlled trial. Gynecol Oncol. 2021;160(2):379–383. doi: 10.1016/j.ygyno.2020.11.029
   PubMed Web of Science ®Google Scholar
• Chopra S, Mangaj A, Sharma A, et al. Management of oligo-metastatic and oligo-recurrent cervical cancer: a pattern of care survey within the EMBRACE research network. Radiother Oncol. 2021;155:151–159. doi: 10.1016/j.radonc.2020.10.037
   PubMed Web of Science ®Google Scholar
• Pang SS, Murphy M, Markham MJ. Current management of locally advanced and metastatic cervical cancer in the United States. JCO Oncol Pract. 2022;18(6):417–422. doi: 10.1200/OP.21.00795
   PubMedGoogle Scholar
• Gadducci A, Sartori E, Maggino T, et al. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a cooperation task force (CTF) study. Eur J Gynaecol Oncol. 2003;6(24):513–516.
   Google Scholar
• D’Augè TG, Giannini A, Bogani G, et al. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. Clin Exp Obstet Gynecol. 2023;50(8):160. doi: 10.31083/j.ceog5008160
   Web of Science ®Google Scholar
• D’oria O, Corrado G, Laganà AS, et al. New advances in cervical cancer: from bench to bedside. Int J Environ Res Public Health. 2022;19(12):7094. doi: 10.3390/ijerph19127094
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–1153. doi: 10.1056/NEJM199904153401502
   PubMed Web of Science ®Google Scholar
• Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–1161. doi: 10.1056/NEJM199904153401503
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743. doi: 10.1056/NEJMoa1309748
   PubMed Web of Science ®Google Scholar
• Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856–1867. doi: 10.1056/NEJMoa2112435
   PubMed Web of Science ®Google Scholar
• Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumabvedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609–619. doi: 10.1016/S1470-2045(21)00056-5
   PubMed Web of Science ®Google Scholar
• Vistad I, Fosså SD, Dahl AA. A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol. 2006;102(3):563–572. doi: 10.1016/j.ygyno.2006.03.050
   PubMed Web of Science ®Google Scholar
• Mishra N, Singh N, Sachdeva M, et al. Sexual dysfunction in cervical cancer survivors: a scoping review. Womens Health Rep (New Rochelle, NY). 2021;2(1):594–607. doi: 10.1089/whr.2021.0035
   PubMedGoogle Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi: 10.1038/nrc3599
   PubMed Web of Science ®Google Scholar
• Allison RR, Sibata CH. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther. 2010;7(2):61–75. doi: 10.1016/j.pdpdt.2010.02.001
   PubMed Web of Science ®Google Scholar
• Aniogo EC, PlackalAdimuriyil George B, Abrahamse H. The role of photodynamic therapy on multidrug resistant breast cancer. Cancer Cell Int. 2019;19(1):91. doi: 10.1186/s12935-019-0815-0
   PubMedGoogle Scholar
• Aniogo EC, George BPA, Abrahamse H. Phthalocyanine induced phototherapy coupled with doxorubicin; a promising novel treatment for breast cancer. Expert Rev Anticancer Ther. 2017;17(8):693–702. doi: 10.1080/14737140.2017.1347505
   PubMed Web of Science ®Google Scholar
• Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250–281. doi: 10.3322/caac.20114
   PubMed Web of Science ®Google Scholar
• Sobhani N, Samadani AA. Implications of photodynamic cancer therapy: an overview of PDT mechanisms basically and practically. J Egypt Natl Canc Inst. 2021;33(1):34. doi: 10.1186/s43046-021-00093-1
   PubMed Web of Science ®Google Scholar
• Hameed S, Bhattarai P, Liang X, et al. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging. Theranostics. 2018;8(19):5501–5518. doi: 10.7150/thno.27721
   PubMed Web of Science ®Google Scholar
• Chilakamarthi U, Giribabu L. Photodynamic therapy: past, present and future. Chem Rec. 2017;17(8):775–802. doi: 10.1002/tcr.201600121
   PubMed Web of Science ®Google Scholar
• Mehta G, Muthusamy S, Maiya BG, et al. Porphyrin–cholic acid–chlorambucil triads: synthesis and light-induced nuclease activity. J Chem Soc Perkin Trans. 1996;(20):2421–2423. doi: 10.1039/P19960002421
   Google Scholar
• El-Hussein A, Manoto SL, Ombinda-Lemboumba S, et al. A review of chemotherapy and photodynamic therapy for lung cancer treatment. Anticancer Agents Med Chem. 2021;21(2):149–161. doi: 10.2174/18715206MTA1uNjQp3
   PubMed Web of Science ®Google Scholar
• Crescenzi E, Chiaviello A, Canti G, et al. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299). Mol Cancer Ther. 2006;5(3):776–785. doi: 10.1158/1535-7163.MCT-05-0425
   PubMed Web of Science ®Google Scholar
• Chen YS, Peng YB, Yao M, et al. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth. Biochem Biophys Res Commun. 2017;487(3):567–572. doi: 10.1016/j.bbrc.2017.04.089
   PubMed Web of Science ®Google Scholar
• Kimura M, Miyajima K, Kojika M, et al. Photodynamic therapy (PDT) with chemotherapy for advanced lung cancer with airway stenosis. Int J Mol Sci. 2015;16(10):25466–25475. doi: 10.3390/ijms161025466
   PubMed Web of Science ®Google Scholar
• Canti G, Nicolin A, Cubeddu R, et al. Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett. 1998;125(1–2):39–44. doi: 10.1016/S0304-3835(97)00502-8
   PubMed Web of Science ®Google Scholar
• Wentrup R, Winkelmann N, Mitroshkin A, et al. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver. 2016;10(3):470–475. doi: 10.5009/gnl15175
   PubMed Web of Science ®Google Scholar
• Crescenzi E, Varriale L, Iovino M, et al. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol Cancer Ther. 2004;3(5):537–544. doi: 10.1158/1535-7163.537.3.5
   PubMed Web of Science ®Google Scholar
• Khdair A, Chen D, Patil Y, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010;141(2):137–144. doi: 10.1016/j.jconrel.2009.09.004
   PubMed Web of Science ®Google Scholar
• Cabral ÁS, Leonel ECR, Candido NM, et al. Combined photodynamic therapy with chloroaluminum phthalocyanine and doxorubicin nanoemulsions in breast cancer model. J Photochem Photobiol B Biol. 2021;218:112181. doi: 10.1016/j.jphotobiol.2021.112181
   PubMed Web of Science ®Google Scholar
• Zhen S, Yi X, Zhao Z, et al. Drug delivery micelles with efficient near-infrared photosensitizer for combined image-guided photodynamic therapy and chemotherapy of drug-resistant cancer. Biomaterials. 2019;218:119330. doi: 10.1016/j.biomaterials.2019.119330
   PubMed Web of Science ®Google Scholar
• Pan Q, Tian J, Zhu H, et al. Tumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer. ACS Biomater Sci Eng. 2020;6(4):2175–2185. doi: 10.1021/acsbiomaterials.0c00163
   PubMed Web of Science ®Google Scholar
• Wang X, Meng G, Zhang S, et al. A reactive 1O2 - responsive combined treatment system of photodynamic and chemotherapy for cancer. Sci Rep. 2016;6(1):1–9. doi: 10.1038/srep29911
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Carobeli LR, Santos ABC, Martins LBM, et al. Photodynamic therapy combined with chemotherapy for treatment of cervical cancer: a protocol for systematic review [Internet]. 2023 [cited 2024 Feb 7]. Available from: https://osf.io/wphn5
   Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10. doi: 10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Faggion CM. Guidelines for reporting pre-clinical in vitro studies on dental materials. J Evid Based Dent Pract. 2012;12(4):182–189. doi: 10.1016/j.jebdp.2012.10.001
   PubMedGoogle Scholar
• Hooijmans CR, Rovers MM, De Vries RBM, et al. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43. doi: 10.1186/1471-2288-14-43
   PubMed Web of Science ®Google Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. doi: 10.1002/jrsm.1411
   PubMed Web of Science ®Google Scholar
• Deng X, Chen Y, Cheng Z, et al. Rational design of a comprehensive cancer therapy platform using temperature-sensitive polymer grafted hollow gold nanospheres: simultaneous chemo/photothermal/photodynamic therapy triggered by a 650 nm laser with enhanced anti-tumor efficacy. Nanoscale. 2016;8(12):6837–6850. doi: 10.1039/C5NR08253F
   PubMed Web of Science ®Google Scholar
• Habiba K, Encarnacion-Rosado J, Garcia-Pabon K, et al. Improving cytotoxicity against cancer cells by chemo-photodynamic combined modalities using silver-graphene quantum dots nanocomposites. Int J Nanomedicine. 2015;11:107–119. doi: 10.2147/IJN.S95440
   PubMed Web of Science ®Google Scholar
• Bano S, Nazir S, Munir S, et al. “Smart” nickel oxide based core-shell nanoparticles for combined chemo and photodynamic cancer therapy. Int J Nanomedicine. 2016;11:3159–3366. doi: 10.2147/IJN.S106533
   PubMed Web of Science ®Google Scholar
• Liu B, Li C, Chen G, et al. Synthesis and optimization of MoS2@Fe3O4-ICG/Pt(IV) nanoflowers for MR/IR/PA bioimaging and combined PTT/PDT/Chemotherapy triggered by 808 nm laser. Adv Sci. 2017;4(8):1600540. doi: 10.1002/advs.201600540
   Web of Science ®Google Scholar
• Yao X, Chen XX, He C, et al. Dual pH-responsive mesoporous silica nanoparticles for efficient combination of chemotherapy and photodynamic therapy. J Mater Chem B. 2015;3(23):4707–4714. doi: 10.1039/C5TB00256G
   PubMed Web of Science ®Google Scholar
• Pei Q, Hu X, Zheng X, et al. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano. 2018;12(2):1630–1641. doi: 10.1021/acsnano.7b08219
   PubMed Web of Science ®Google Scholar
• Liu LH, Qiu WX, Li B, et al. A red light activatable multifunctional prodrug for image-guided photodynamic therapy and cascaded chemotherapy. Adv Funct Mater. 2016;26(34):6257–6269. doi: 10.1002/adfm.201602541
   Web of Science ®Google Scholar
• Liu L, Wang R, Wang C, et al. Light-triggered release of drug conjugates for an efficient combination of chemotherapy and photodynamic therapy. Biomater Sci. 2018;6(5):997–1001. doi: 10.1039/C7BM01114H
   PubMed Web of Science ®Google Scholar
• Fan W, Shen B, Bu W, et al. A smart upconversion-based mesoporous silica nanotheranostic system for synergetic chemo-/radio-/photodynamic therapy and simultaneous MR/UCL imaging. Biomaterials. 2014;35(32):8992–9002. doi: 10.1016/j.biomaterials.2014.07.024
   PubMed Web of Science ®Google Scholar
• Zheng T, Wang W, Wu F, et al. Zwitterionic polymer-gated Au@TiO2 core-shell nanoparticles for imaging-guided combined cancer therapy. Theranostics. 2019;9(17):5035–5048. doi: 10.7150/thno.35418
   PubMed Web of Science ®Google Scholar
• Zhang T, Fu L, Zheng X, et al. Two-photon excited organic nanoparticles for chemo-photodynamic therapy. Dye Pigment. 2019;167:195–203. doi: 10.1016/j.dyepig.2019.04.038
   Web of Science ®Google Scholar
• De Freitas LM, Soares CP, Fontana CR. Synergistic effect of photodynamic therapy and cisplatin: a novel approach for cervical cancer. J Photochem Photobiol B Biol. 2014;140:365–373. doi: 10.1016/j.jphotobiol.2014.08.021
   PubMed Web of Science ®Google Scholar
• Wei XQ, Ma HQ, Liu AH, et al. Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on hela cells. Asian Pac J Cancer Prev. 2013;14(5):3023–3028. doi: 10.7314/APJCP.2013.14.5.3023
   PubMedGoogle Scholar
• Cao W, Zeng XX, Liu G, et al. Porphine functionalized nanoparticles of star-shaped poly(ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 1000 succinate biodegradable copolymer for chemophotodynamic therapy on cervical cancer. Acta Biomater. 2015;26:145–148. doi: 10.1016/j.actbio.2015.08.016
   PubMed Web of Science ®Google Scholar
• de Freitas LM, Serafim RB, de Sousa JF, et al. Photodynamic therapy combined to cisplatin potentiates cell death responses of cervical cancer cells. BMC Cancer. 2017;17:1–12.
   PubMed Web of Science ®Google Scholar
• Vivero-Escoto JL, Elnagheeb M. Mesoporous silica nanoparticles loaded with cisplatin and phthalocyanine for combination chemotherapy and photodynamic therapy in vitro. Nanomaterials. 2015;5(4):2302–2316. doi: 10.3390/nano5042302
   Web of Science ®Google Scholar
• Dong J, Zhang Y, Guo P, et al. Gqds/hMSN nanoplatform: singlet oxygen generation for photodynamic therapy. J Drug Deliv Sci Technol. 2021;61:102127. doi: 10.1016/j.jddst.2020.102127
   Web of Science ®Google Scholar
• Zhang HX, Lin HH, Su D, et al. Enzyme-activated multifunctional prodrug combining site-specific chemotherapy with light-triggered photodynamic therapy. Mol Pharm. 2022;19(2):630–641. doi: 10.1021/acs.molpharmaceut.1c00761
   PubMedGoogle Scholar
• Wang T, Zhu D, Liu G, et al. DTX-loaded star-shaped TAPP-PLA-b-TPGS nanoparticles for cancer chemical and photodynamic combination therapy. RSC Adv. 2015;5(62):50617–50627. doi: 10.1039/C5RA09042C
   Web of Science ®Google Scholar
• Li N, Xiang MH, Liu JW, et al. DNA polymer nanoparticles programmed via Supersandwich Hybridization for Imaging and therapy of cancer cells. Anal Chem. 2018;90(21):12951–12958. doi: 10.1021/acs.analchem.8b03253
   PubMed Web of Science ®Google Scholar
• Benito-Miguel M, Blanco MD, Gómez C. Assessment of sequential combination of 5-fluorouracil-loaded-chitosan-nanoparticles and ALA-photodynamic therapy on HeLa cell line. Photodiagnosis Photodyn Ther. 2015;12(3):466–475. doi: 10.1016/j.pdpdt.2015.05.001
   PubMed Web of Science ®Google Scholar
• Fang J, Wang Q, Yang G, et al. Albumin-MnO2 gated hollow mesoporous silica nanosystem for modulating tumor hypoxia and synergetic therapy of cervical carcinoma. Colloids Surf B Biointerfaces. 2019;179:250–259.
   PubMed Web of Science ®Google Scholar
• Dong C, Liu Z, Wang S, et al. A protein–polymer bioconjugate-coated upconversion nanosystem for simultaneous tumor cell imaging, photodynamic therapy, and chemotherapy. ACS Appl Mater Interfaces. 2016;8(48):32688–32698. doi: 10.1021/acsami.6b11803.
   PubMed Web of Science ®Google Scholar
• Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50–67. doi: 10.1053/j.seminoncol.2005.11.002
   PubMed Web of Science ®Google Scholar
• Han C, Zhang CC, Ma T, et al. Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect. Acta Biomater. 2018;77:268–281. doi: 10.1016/j.actbio.2018.07.018
   PubMed Web of Science ®Google Scholar
• Fu D, Calvo JA, Samson LD. SERIES: genomic instability in cancer balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12:104. doi: 10.1038/nrc3185
   PubMed Web of Science ®Google Scholar
• Puyo S, Montaudon D, Pourquier P. From old alkylating agents to new minor groove binders. Crit Rev Oncol Hematol. 2014;89(1):43–61. doi: 10.1016/j.critrevonc.2013.07.006
   PubMed Web of Science ®Google Scholar
• Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. doi: 10.1016/j.bioorg.2019.102925
   PubMed Web of Science ®Google Scholar
• Kirveliene V, Grazeliene G, Dabkeviciene D, et al. Schedule-dependent interaction between doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo. Cancer Chemother Pharmacol. 2006;57(1):65–72. doi: 10.1007/s00280-005-0006-7
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Walt H, Haller U, et al. Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient. Cancer Chemother Pharmacol. 2003;51(2):147–154. doi: 10.1007/s00280-002-0549-9
   PubMed Web of Science ®Google Scholar
• Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi: 10.1016/j.ejphar.2014.07.025
   PubMed Web of Science ®Google Scholar
• de Brito RV, Mancini MW, Palumbo MDN, et al. The rationale for “laser-induced thermal therapy (LITT) and intratumoral cisplatin” approach for cancer treatment. Int J Mol Sci. 2022;23(11):5934. doi: 10.3390/ijms23115934
   PubMed Web of Science ®Google Scholar
• Dowdy SC, Boardman CH, Wilson TO, et al. Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. Am J Obstet Gynecol. 2002;186(6):1167–1173. doi: 10.1067/mob.2002.123820
   PubMed Web of Science ®Google Scholar
• Ge R, Ahn JC, Shin JI, et al. An in vitro and in vivo study of combination therapy with Photogem®-mediated photodynamic therapy and cisplatin on mouse cancer cells (CT-26). Photomed Laser Surg. 2011;29(3):155–160. doi: 10.1089/pho.2009.2750
   PubMed Web of Science ®Google Scholar
• Saris CP, Van de Vaart PJM, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis. 1996;17(12):2763–2769. doi: 10.1093/carcin/17.12.2763
   PubMed Web of Science ®Google Scholar
• Aghajanzadeh M, Zamani M, Kouchi FR, et al. Synergic antitumor effect of photodynamic therapy and chemotherapy mediated by nano drug delivery systems. Pharmaceutics. 2022;14(2):322. doi: 10.3390/pharmaceutics14020322
   PubMed Web of Science ®Google Scholar
• Mariño-Ocampo N, Dibona-Villanueva L, Escobar-Álvarez E, et al. Recent photosensitizer developments, delivery strategies and combination-based approaches for photodynamic therapy †. Photochem Photobiol. 2023;99(2):469–497. doi: 10.1111/php.13749
   PubMed Web of Science ®Google Scholar
• Jain R, Mohanty S, Sarode I, et al. Multifunctional photoactive nanomaterials for photodynamic therapy against tumor: recent advancements and perspectives. Pharmaceutics. 2023;15(1):109. doi: 10.3390/pharmaceutics15010109
   Web of Science ®Google Scholar
• Edis Z, Wang J, Waqas MK, et al. Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int J Nanomedicine. 2021;16:1313–1330. doi: 10.2147/IJN.S289443
   PubMed Web of Science ®Google Scholar
• Teplensky MH, Fantham M, Li P, et al. Temperature treatment of highly porous zirconium-containing metal–organic frameworks extends drug delivery release. J Am Chem Soc. 2017;139(22):7522–7532. doi: 10.1021/jacs.7b01451
   PubMed Web of Science ®Google Scholar
• Lajunen T, Kontturi LS, Viitala L, et al. Indocyanine green-loaded liposomes for light-triggered drug release. Mol Pharm. 2016;13(6):2095–2107. doi: 10.1021/acs.molpharmaceut.6b00207
   PubMedGoogle Scholar
• Wang H, Gauthier M, Kelly JR, et al. Targeted ultrasound-assisted cancer-selective chemical labeling and subsequent cancer imaging using click chemistry. Angew Chem Int Ed Engl. 2016;55(18):5452–5456. doi: 10.1002/anie.201509601
   PubMed Web of Science ®Google Scholar
• Awino JK, Gudipati S, Hartmann AK, et al. Nucleic Acid Nanocapsules for Enzyme-Triggered Drug Release. J Am Chem Soc. 2017;139(18):6278–6281. doi: 10.1021/jacs.6b13087
   PubMed Web of Science ®Google Scholar
• Yang H, Wang Q, Huang S, et al. Smart pH/Redox dual-responsive nanogels for on-demand intracellular anticancer drug release. ACS Appl Mater Interfaces. 2016;8(12):7729–7738. doi: 10.1021/acsami.6b01602
   PubMed Web of Science ®Google Scholar
• Couleaud P, Morosini V, Frochot C, et al. Silica-based nanoparticles for photodynamic therapy applications. Nanoscale. 2010;2(7):1083–1095. doi: 10.1039/c0nr00096e
   PubMed Web of Science ®Google Scholar
• Vivero-Escoto JL, Slowing II, Lin VSY, et al. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010;6(18):1952–1967. doi: 10.1002/smll.200901789
   PubMed Web of Science ®Google Scholar
• Postiglione I, Chiaviello A, Palumbo G. Enhancing photodynamyc therapy efficacy by combination therapy: dated, Current and oncoming strategies. Cancers (Basel). 2011;3(2):2597–2629. doi: 10.3390/cancers3022597
   PubMedGoogle Scholar
• Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853–858. doi: 10.4103/0973-1482.139267
   PubMed Web of Science ®Google Scholar
• Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy – a model for carcinogenesis. J Photochem Photobiol B. 1993;20(1):5–22. doi: 10.1016/1011-1344(93)80127-U
   PubMed Web of Science ®Google Scholar
• Imran M, Ramzan M, Qureshi AK, et al. Emerging applications of porphyrins and metalloporphyrins in biomedicine and diagnostic magnetic resonance imaging. Biosensors (Basel). 2018;8(4):95. doi: 10.3390/bios8040095
   PubMedGoogle Scholar
• Ge J, Lan M, Zhou B, et al. A graphene quantum dot photodynamic therapy agent with high singlet oxygen generation. Nat Commun. 2014;5(1):1–8. doi: 10.1038/ncomms5596
   Google Scholar
• Zhao X, Yang L, Li X, et al. Functionalized graphene oxide nanoparticles for cancer cell-specific delivery of antitumor drug. Bioconjug Chem. 2015;26(1):128–136. doi: 10.1021/bc5005137
   PubMed Web of Science ®Google Scholar
• Shewach DS, Kuchta RD. Introduction to cancer chemotherapeutics. Chem Rev. 2009;109(7):2859. doi: 10.1021/cr900208x
   PubMed Web of Science ®Google Scholar
• Walko CM, Lindley C. Capecitabine: A review. Clin Ther. 2005;27(1):23–44. doi: 10.1016/j.clinthera.2005.01.005
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Topoisomerase Inhibitors. [Updated 2020 Sep 12;cited 2024 Feb 07]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548372/
   Google Scholar
• Liang X, Wu Q, Luan S, et al. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur J Med Chem. 2019;171:129–168. doi: 10.1016/j.ejmech.2019.03.034
   PubMed Web of Science ®Google Scholar
• Pratt SE, Durland-Busbice S, Shepard RL, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013;19(5):1159–1168. doi: 10.1158/1078-0432.CCR-12-1184
   PubMed Web of Science ®Google Scholar
• Göksel M, Durmuş M, Biyiklioglu Z. Synthesis and photodynamic activities of novel silicon(IV) phthalocyanines axially substituted with water soluble groups against HeLa cancer cell line. Dalton Trans. 2021;50(7):2570–2584. doi: 10.1039/D0DT03858J
   PubMed Web of Science ®Google Scholar
• Avdoshina DV, Kondrashova AS, Belikova MG, et al. Murine models of chronic viral infections and associated cancers. Mol Biol. 2022;56:649. doi: 10.1134/S0026893322050028
   PubMed Web of Science ®Google Scholar
• Hu K, Wang W, Liu X, et al. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiat Oncol. 2018;13(1):1–7. doi: 10.1186/s13014-018-1197-5
   PubMedGoogle Scholar
• Xie X, Song K, Cui B, et al. A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB–IIA cervical cancer. Int J Clin Oncol. 2018;23(3):522–531. doi: 10.1007/s10147-017-1225-8
   PubMed Web of Science ®Google Scholar